For the year ending 2025-12-31, TOVX has $38,239K in assets. $22,856K in debts. $13,056K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 13,056 | |||
| Tax credit receivable | 3,351 | |||
| Prepaid expenses and other current assets | 1,060 | |||
| Total current assets | 17,467 | |||
| Property and equipment, net | 222 | |||
| Restricted cash | 46 | |||
| Right of use asset | 803 | |||
| In-process research and development | 19,619 | |||
| Deposits and other assets | 82 | |||
| Total assets | 38,239 | |||
| Accounts payable | 1,014 | |||
| Accrued expenses | 6,276 | |||
| Accrued employee benefits | 443 | |||
| Deferred research and development tax credit-current portion | 1,675 | |||
| Loans payable-current | 57 | |||
| Operating lease liability-current portion | 549 | |||
| Total current liabilities | 10,014 | |||
| Non-current contingent consideration | 10,004 | |||
| Loan payable - non-current | 1,671 | |||
| Non-current deferred research and development tax credit | 815 | |||
| Non-current operating lease liability | 352 | |||
| Total liabilities | 22,856 | |||
| Common stock, 0.001 par value 350,000,000 shares authorized, 35,717,159 issued and 35,688,350 outstanding at december 31, 2025 and 2,811,259 issued and 2,782,449 outstanding at december 31, 2024 | 34 | |||
| Additional paid-in capital | 373,592 | |||
| Treasury stock at cost, 28,809 shares at december 31, 2025 and at december 31, 2024 | 288 | |||
| Accumulated other comprehensive income (loss) | 755 | |||
| Accumulated deficit | -358,710 | |||
| Total stockholders' equity | 15,383 | |||
| Total liabilities and stockholders' equity | 38,239 | |||
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)